Q2 2024 LeMaitre Vascular Inc Earnings Call Transcript
Key Points
- LeMaitre Vascular Inc (LMAT) reported a strong Q2 2024 with 12% organic sales growth and 44% EPS growth.
- The company experienced broad-based growth across 7 of its 12 product lines, with notable increases in RestoreFlow allografts (30%), bovine patches (12%), and shunts (22%).
- APAC was the strongest region with a 20% increase, driven by direct market conversions in Thailand and Korea.
- The company added seven sales representatives in Q2, aiming for 155 to 160 by year-end, focusing on North America to optimize territory sizes.
- Gross margin improved to 68.9%, up 490 basis points year-over-year, driven by productivity improvements and higher average selling prices (ASPs).
- The company faces regulatory challenges in Europe, with only 14 out of 22 MDR CE marks received, and some approvals expected as late as 2025.
- There are higher costs anticipated for RestoreFlow, which could impact future gross margins.
- The hiring process for sales representatives remains challenging, despite broader market trends suggesting easier hiring conditions.
- The company has not yet secured any new acquisitions, despite ongoing efforts and discussions with potential targets.
- Pricing increases, while beneficial, may not be sustainable long-term, and the company has not yet set prices for 2025.
Welcome to the LeMaitre Vascular Q2 2024 financial results conference call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. JJ Pellegrino, Chief Financial Officer for LeMaitre Vascular. Please go ahead sir.
Good afternoon, and thank you for joining us on our Q2 2024 conference call. With me on today's call is our CEO, George LeMaitre, and our President, Dave Roberts. Before we begin, I'll read our Safe Harbor statements. Today, we will make some forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties, wherever possible, we will tried to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast and similar expressions.
Our forward looking statements are based on our estimates and assumptions as of today, August f1, 2024 and should not be relied upon as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
